The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts

被引:139
作者
Cano, Stefan J.
Posner, Holly B. [2 ]
Moline, Margaret L. [3 ]
Hurt, Stephen W. [3 ,4 ]
Swartz, Jina [5 ]
Hsu, Tim [3 ]
Hobart, Jeremy C. [1 ]
机构
[1] Peninsula Coll Med & Dent, Dept Clin Neurosci, Clin Neurol Res Grp, Plymouth PL6 8BX, Devon, England
[2] Pfizer Inc, New York, NY USA
[3] Eisai Neurosci Prod Creat Unit, Woodcliff Lake, NJ USA
[4] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[5] Eisai Neurosci Prod Creat Unit, Hatfield, Herts, England
关键词
PLACEBO-CONTROLLED TRIAL; COGNITIVE IMPAIRMENT; MULTIPLE-SCLEROSIS; ASSESSMENT SCALE; RATING-SCALE; DOUBLE-BLIND; DONEPEZIL;
D O I
10.1136/jnnp.2009.204008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The Alzheimer's Disease Assessment Scale Cognitive Behavior Section (ADAS-cog), a measure of cognitive performance, has been used widely in Alzheimer's disease trials. Its key role in clinical trials should be supported by evidence that it is both clinically meaningful and scientifically sound. Its conceptual and neuropsychological underpinnings are well-considered, but its performance as an instrument of measurement has received less attention. Objective To examine the traditional psychometric properties of the ADAS-cog in a large sample of people with Alzheimer's disease. Methods Data from three clinical trials of donepezil (Aricept) in mild-to-moderate Alzheimer's disease (n=1421; MMSE 10-26) were analysed at both the scale and component level. Five psychometric properties were examined using traditional psychometric methods. These methods of examination underpin upcoming Food and Drug Administration recommendations for patient rating scale evaluation. Results At the scale-level, criteria tested for data completeness, scaling assumptions (eg, component total correlations: 0.39-0.67), targeting (no floor or ceiling effects), reliability (eg, Cronbach's alpha: = 0.84; test-retest intraclass correlations: 0.93) and validity (correlation with MMSE: -0.63) were satisfied. At the component level, 7 of 11 ADAS-cog components had substantial ceiling effects (range 40-64%). Conclusions Performance was satisfactory at the scale level, but most ADAS-cog components were too easy for many patients in this sample and did not reflect the expected depth and range of cognitive performance. The clinical implication of this finding is that the ADAS-cog's estimate of cognitive ability, and its potential ability to detect differences in cognitive performance under treatment, could be improved. However, because of the limitations of traditional psychometric methods, further evaluations would be desirable using additional rating scale analysis techniques to pinpoint specific improvements.
引用
收藏
页码:1363 / 1368
页数:6
相关论文
共 26 条
[1]  
Aaronson N, 2002, QUAL LIFE RES, V11, P193
[2]   Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].
Aisen, PS ;
Schafer, KA ;
Grundman, M ;
Pfeiffer, E ;
Sano, M ;
Davis, KL ;
Farlow, MR ;
Jin, S ;
Thomas, RG ;
Thal, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826
[3]  
*ALZH ASS, 2008, ALZH DIS FACTS FIG
[4]  
Andrich D., 2011, Rasch Models for Measurement
[5]  
[Anonymous], 2009, PAT REP OUTC MEAS US
[6]   Alzheimer's disease [J].
Scheltens, Philip ;
De Strooper, Bart ;
Kivipelto, Miia ;
Holstege, Henne ;
Chetelat, Gael ;
Teunissen, Charlotte E. ;
Cummings, Jeffrey ;
van der Flier, Wiesje M. .
LANCET, 2021, 397 (10284) :1577-1590
[7]   Forecasting the global burden of Alzheimer's disease [J].
Brookmeyer, Ron ;
Johnson, Elizabeth ;
Ziegler-Graham, Kathryn ;
Arrighi, H. Michael .
ALZHEIMERS & DEMENTIA, 2007, 3 (03) :186-191
[8]   The effects of donepezil in Alzheimer's disease -: Results from a multinational trial [J].
Burns, A ;
Rossor, M ;
Hecker, J ;
Gauthier, S ;
Petit, H ;
Möller, HJ ;
Rogers, SL ;
Friedhoff, LT .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (03) :237-244
[9]   International Cooperative Ataxia Rating Scale (ICARS): Appropriate for studies of Friedreich's ataxia? [J].
Cano, SJ ;
Hobart, JC ;
Hart, PE ;
Korlipara, LVP ;
Schapira, AH ;
Cooper, JM .
MOVEMENT DISORDERS, 2005, 20 (12) :1585-1591
[10]   Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL [J].
Dichgans, Martin ;
Markus, Hugh S. ;
Salloway, Stephen ;
Verkkoniemi, Auli ;
Moline, Margaret ;
Wang, Qin ;
Posner, Holly ;
Chabriat, Hugues S. .
LANCET NEUROLOGY, 2008, 7 (04) :310-318